Financial Advantage’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | $1.56M | Sell |
12,800
-8,696
| -40% | -$1.16M | 2.39% | 21 |
|
|
2023
Q2 | $3.02M | Buy |
21,496
+116
| +0.5% | +$16K | 2.7% | 17 |
|
|
2023
Q1 | $3.02M | Buy |
21,380
+37
| +0.2% | +$5.29K | 2.75% | 15 |
|
|
2022
Q4 | $3.34M | Sell |
21,343
-509
| -2% | -$73.1K | 3.1% | 16 |
|
|
2022
Q3 | $2.68M | Buy |
21,852
+121
| +0.6% | +$15.9K | 2.65% | 20 |
|
|
2022
Q2 | $2.89M | Buy |
21,731
+52
| +0.2% | +$7.09K | 2.66% | 18 |
|
|
2022
Q1 | $2.97M | Buy |
21,679
+121
| +0.6% | +$16.9K | 2.4% | 21 |
|
|
2021
Q4 | $3.73M | Sell |
21,558
-147
| -0.7% | -$22.4K | 3.08% | 13 |
|
|
2021
Q3 | $3.15M | Sell |
21,705
-139
| -0.6% | -$20.3K | 2.74% | 15 |
|
|
2021
Q2 | $2.88M | Sell |
21,844
-480
| -2% | -$62.8K | 2.46% | 20 |
|
|
2021
Q1 | $2.87M | Buy |
22,324
+79
| +0.4% | +$9.73K | 2.47% | 22 |
|
|
2020
Q4 | $2.65M | Sell |
22,245
-1,532
| -6% | -$187K | 2.45% | 20 |
|
|
2020
Q3 | $2.72M | Sell |
23,777
-6,468
| -21% | -$764K | 2.58% | 19 |
|
|
2020
Q2 | $3.45M | Sell |
30,245
-298
| -1% | -$31.6K | 2.61% | 20 |
|
|
2020
Q1 | $2.45M | Sell |
30,543
-685
| -2% | -$70.9K | 2.14% | 21 |
|
|
2019
Q4 | $3.33M | Buy |
31,228
+855
| +3% | +$89.2K | 2.29% | 20 |
|
|
2019
Q3 | $3.25M | Buy |
30,373
+57
| +0.2% | +$5.85K | 2.21% | 22 |
|
|
2019
Q2 | $3.09M | Buy |
30,316
+104
| +0.3% | +$9.99K | 2.11% | 23 |
|
|
2019
Q1 | $2.72M | Buy |
30,212
+128
| +0.4% | +$11.1K | 1.94% | 23 |
|
|
2018
Q4 | $2.5M | Sell |
30,084
-159
| -0.5% | -$14.9K | 2.05% | 23 |
|
|
2018
Q3 | $3.26M | Buy |
30,243
+25
| +0.1% | +$2.74K | 2.46% | 22 |
|
|
2018
Q2 | $3.32M | Sell |
30,218
-329
| -1% | -$34.3K | 2.52% | 20 |
|
|
2018
Q1 | $3.06M | Buy |
30,547
+51
| +0.2% | +$5.22K | 2.45% | 20 |
|
|
2017
Q4 | $3M | Buy |
30,496
+145
| +0.5% | +$13.7K | 2.38% | 20 |
|
|
2017
Q3 | $2.84M | Buy |
30,351
+569
| +2% | +$60.4K | 2.31% | 20 |
|
|
2017
Q2 | $3.31M | Sell |
29,782
-575
| -2% | -$60.8K | 2.81% | 17 |
|
|
2017
Q1 | $2.98M | Sell |
30,357
-16,032
| -35% | -$1.53M | 2.52% | 21 |
|
|
2016
Q4 | $4.26M | Buy |
46,389
+456
| +1% | +$39.3K | 3.87% | 13 |
|
|
2016
Q3 | $3.89M | Sell |
45,933
-19,841
| -30% | -$1.67M | 3.59% | 14 |
|
|
2016
Q2 | $5.36M | Buy |
65,774
+23
| +0% | +$1.75K | 4.77% | 6 |
|
|
2016
Q1 | $4.7M | Buy |
65,751
+529
| +0.8% | +$35.5K | 4.26% | 7 |
|
|
2015
Q4 | $4.64M | Sell |
65,222
-500
| -0.8% | -$33.6K | 4.89% | 6 |
|
|
2015
Q3 | $4.04M | Buy |
65,722
+1,288
| +2% | +$90K | 3.76% | 12 |
|
|
2015
Q2 | $4.67M | Sell |
64,434
-970
| -1% | -$71.6K | 4.48% | 7 |
|
|
2015
Q1 | $5.03M | Sell |
65,404
-10,418
| -14% | -$746K | 4.43% | 8 |
|
|
2014
Q4 | $5.08M | Buy |
75,822
+31,104
| +70% | +$1.96M | 4.71% | 8 |
|
|
2014
Q3 | $2.71M | Buy |
44,718
+660
| +1% | +$40.7K | 2.57% | 19 |
|
|
2014
Q2 | $2.59M | Sell |
44,058
-564
| -1% | -$33K | 2.53% | 18 |
|
|
2014
Q1 | $2.58M | Sell |
44,622
-3,715
| -8% | -$199K | 2.52% | 18 |
|
|
2013
Q4 | $2.59M | Buy |
+48,337
| New | +$2.87M | 2.19% | 18 |
|
Other funds holding DGX
Financial Advantage's DGX Position: Q3 2023 in Review
Financial Advantage reduced its Quest Diagnostics (DGX) stake by 40% in Q3 2023, selling an estimated $1.16M and leaving 12,800 shares worth $1.56M. The position accounts for 2.39% of the portfolio, ranked #21.
Financial Advantage first reported a position in DGX in Q4 2013 and has held it in 40 quarters since. The position peaked at $5.36M in Q2 2016. 794 funds tracked by Wall St. Rank hold DGX as of Q3 2023.
- Financial Advantage held 12,800 shares of Quest Diagnostics worth $1.56M as of Q3 2023.
- Financial Advantage sold 8,696 Quest Diagnostics shares in Q3 2023, an estimated $1.16M.
- Quest Diagnostics made up 2.39% of Financial Advantage's portfolio in Q3 2023, its #21 holding.
- Financial Advantage first reported a position in Quest Diagnostics in Q4 2013 and has held it in 40 quarters since.
- Financial Advantage's Quest Diagnostics position peaked at $5.36M in Q2 2016.
- 794 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2023.
Based on Financial Advantage's 13F filing for Q3 2023, filed 7 Nov 2023.